MODERATE
52
The Alpha Score is an informational signal based on public SEC fillings. It is not investment advice.
CEOJOURNAL SIGNAL SUMMARY·GENERATED FROM PUBLIC SEC FILINGS
Phillip Frost, MD made an open-market purchase of Opko Health, Inc. on 2025-11-21, investing approximately $768,807. This is a CEOJournal signal summary placeholder — full narrative pending Claude Haiku enrichment.
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
Score Components
COMPOSITE ALPHA SCORE
52
Score calculated from open-market purchases only; 10b5-1 preplanned trades excluded; not investment advice.
OPPORTUNISM
Proxy from ownership-change magnitude. Real Opportunism signal will use %52W proximity once price data is in pipeline.
CONVICTION
Log-scaled from trade size. Real Conviction signal will use trade $ ÷ total compensation once DEF 14A data is in pipeline.
PATTERN
Placeholder — 90-day qualifying buy count requires historical Form 4 scrapes (Phase 2).
CLUSTER
Count of other insiders buying the same ticker in our current dataset window.
TRACK RECORD
Placeholder — executive tenure × prior buy P&L requires historical price tracking (Phase 2).
FORM 4 TRANSACTION HISTORYSOURCE: SEC EDGAR
| DATE | TRANSACTION TYPE | CODE | SHARES | PRICE | TOTAL VALUE | 10b5-1 | SCORE |
|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Open-Market Purchase | P | 580,000 | $1.33 | $768,807 | N/A | 52 |
Data sourced from SEC EDGAR Form 4 filings, updated within 24 hours.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
EXECUTIVE PROFILE
Phillip Frost, MD
CEO, COB, 10%
Phillip Frost, M.D. has served as Chief Executive Officer and Chairman of the Board of Opko Health, Inc. since March 2007. He previously held the same positions at IVAX Corporation from 1987 until its acquisition by Teva in January 2006. Dr. Frost has founded several pharmaceutical companies and has extensive experience in drug development and commercialization.
EDUCATION
Pending DEF 14A enrichment.
BOARD SEATS
- Cocrystal Pharma, Inc. · Director
- Non-Invasive Monitoring Systems, Inc. · Director
- Grove Bank & Trust · Director
- Morgan Solar · Director
- University of Miami · Board of Trustees Member
- Miami Jewish Home for the Aged · Trustee
- Mount Sinai Medical Center · Executive Committee Member
- Temple Emanu-El · Chairman
- Tel Aviv University · Governor
- The Phillip and Patricia Frost Museum of Science · Executive Committee Member
- Smithsonian Institute · Regent
- Northrop Grumman · Director
- Ladenburg Thalmann Financial Services Inc. · Director and Chairman
- Castle Brands · Director
COMPENSATION & OWNERSHIP ·SOURCE: DEF 14A PROXY
ANNUAL BASE SALARY
$960,000
TOTAL COMPENSATION
$2,277,200
SHARES HELD
250,402,576
EST. HOLDINGS VALUE
$365.59M
as of May 30, 2026 close
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
RELATED SIGNALS